According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Other analysts have also recently issued reports about the company. HC Wainwright reissued a hold rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. ValuEngine raised Syros Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, February 4th. Wedbush cut Syros Pharmaceuticals from an outperform rating to a neutral rating and set a $9.00 price objective for the company. in a report on Friday, January 17th. Cowen reissued a buy rating on shares of Syros Pharmaceuticals in a report on Wednesday, December 18th. Finally, BidaskClub cut Syros Pharmaceuticals from a hold rating to a sell rating in a report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $12.89.
Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $194,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $138,000. State Street Corp lifted its stake in Syros Pharmaceuticals by 19.7% in the 3rd quarter. State Street Corp now owns 674,261 shares of the company’s stock valued at $6,999,000 after acquiring an additional 110,929 shares in the last quarter. ARK Investment Management LLC lifted its stake in Syros Pharmaceuticals by 32.4% in the 4th quarter. ARK Investment Management LLC now owns 5,077,807 shares of the company’s stock valued at $35,088,000 after acquiring an additional 1,243,079 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Syros Pharmaceuticals by 191.6% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,633,773 shares of the company’s stock valued at $48,099,000 after acquiring an additional 3,044,728 shares in the last quarter.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
See Also: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.